Tentarix Biotherapeutics uses its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics with cell-specific activity. The company is focused on creating multifunctional biologics intended to target previously undruggable targets and transform biologics. With the new Series B financing and a collaboration with Gilead, management says the company is well-capitalized to expand its pipeline of cell-specific, conditionally active therapeutics. President and CEO Paul Grayson stated the financing extends its cash runway and enables pipeline expansion. Since inception Tentarix has raised $132 million in total from equity and upfront partnership payments, including the most recent $35 million Series B. The company is based in San Diego. Tentarix develops next-generation antibody-based multifunctional biotherapeutics that can conditionally activate or inhibit specific cell populations, enabling cell-type selectivity and unique functions. Its proprietary platform enables high-throughput discovery and optimization of multifunctional molecules with robust mammalian expression and molecular developability. The company has generated proof-of-concept data across multiple receptor classes and is advancing a lead program that engages IL2R gamma and IL2R beta subunits plus additional subunits that target a specific T cell subset, producing potent activity only when all targets are engaged. Tentarix is also advancing programs in cell type–specific reprogramming and cell population–specific delivery and internalization. A seasoned leadership team and more than 30 experts in protein engineering, cell surface proteomics, and discovery technology are assembled in San Diego, California and Vancouver, British Columbia. The company intends to translate its platform across oncology and autoimmune indications.

Total raised

$85M

Funding rounds

2

Latest round

Series B

Latest activity

Sep 2023